Skip to main content
SpringerLink
Log in

Fortgeschrittenes Melanom: Checkpointinhibitoren im Vergleich

  • Literatur kompakt_Tumoren der Haut
  • Published:
Im Focus Onkologie Aims and scope

In der Phase-III-Studie KEYNOTE-006 wurde Pembrolizumab mit Ipilimumab, der bisherigen Standardtherapie bei fortgeschrittenem Melanom, verglichen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Judith Neumaier

  2. Hauttumorzentrum Nürnberg Klinikum Nürnberg Nord, Nord, Deutschland

    Dirk Debus

Authors
  1. Judith Neumaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dirk Debus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Debus.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neumaier, J., Debus, D. Fortgeschrittenes Melanom: Checkpointinhibitoren im Vergleich. Im Focus Onkologie 18, 43–44 (2015). https://doi.org/10.1007/s15015-015-2150-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-015-2150-1

Search

Navigation